ELI LILLY AND COMPANY Payments to Acquire Other Investments
ELI LILLY AND COMPANY (LLY) reported Payments to Acquire Other Investments of $604.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireOtherInvestments · last filed 2026-08-05
- ELI LILLY AND COMPANY payments to acquire other investments for the quarter ending 2026-06-30 was $307.00M, a 79.53% increase year-over-year.
- ELI LILLY AND COMPANY payments to acquire other investments for the quarter ending 2026-03-31 was $297.00M, a 50.76% increase year-over-year.
- ELI LILLY AND COMPANY payments to acquire other investments for the quarter ending 2025-12-31 was $127.00M, a 16.39% decline year-over-year.
- ELI LILLY AND COMPANY payments to acquire other investments for the quarter ending 2025-09-30 was $150.00M, a 45.45% decline year-over-year.
- ELI LILLY AND COMPANY payments to acquire other investments for fiscal 2025 was $645.00M, a 4.73% decline from fiscal 2024.
- ELI LILLY AND COMPANY payments to acquire other investments for fiscal 2024 was $677.00M, a 7.39% decline from fiscal 2023.
- ELI LILLY AND COMPANY payments to acquire other investments for fiscal 2023 was $731.00M, a 21.79% increase from fiscal 2022.
- ELI LILLY AND COMPANY payments to acquire other investments for fiscal 2022 was $600.20M, a 35.46% decline from fiscal 2021.
| Period end | Payments to Acquire Other Investments 3 month | Payments to Acquire Other Investments 3 month as first filed | Payments to Acquire Other Investments 6 month | Payments to Acquire Other Investments 6 month as first filed | Payments to Acquire Other Investments 9 month | Payments to Acquire Other Investments 9 month as first filed | Payments to Acquire Other Investments 12 month | Payments to Acquire Other Investments 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $307.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $604.00M 10-Q · filed 2026-08-05 | $731.00M derived: sum of 3 quarters · filed 2026-08-05 | $881.00M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | $297.00M 10-Q · filed 2026-04-30 | $424.00M derived: sum of 2 quarters · filed 2026-04-30 | $574.00M derived: sum of 3 quarters · filed 2026-04-30 | $745.00M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $127.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $277.00M derived: sum of 2 quarters · filed 2026-02-12 | $448.00M derived: sum of 3 quarters · filed 2026-08-05 | $645.00M 10-K · filed 2026-02-12 | ||||
| 2025-09-30 | $150.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $321.00M derived: sum of 2 quarters · filed 2026-08-05 | $518.00M 10-Q · filed 2025-10-30 | $669.90M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | $171.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $368.00M 10-Q · filed 2026-08-05 | $367.90M 10-Q · filed 2025-08-07 | $519.90M derived: sum of 3 quarters · filed 2026-08-05 | $794.90M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-03-31 | $197.00M 10-Q · filed 2026-04-30 | $196.70M 10-Q · filed 2025-05-01 | $348.90M derived: sum of 2 quarters · filed 2026-04-30 | $623.90M derived: sum of 3 quarters · filed 2026-04-30 | $756.90M derived: sum of 4 quarters · filed 2026-04-30 | |||
| 2024-12-31 | $151.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $426.90M derived: sum of 2 quarters · filed 2026-02-12 | $559.90M derived: sum of 3 quarters · filed 2026-02-12 | $677.00M 10-K · filed 2026-02-12 | $677.30M 10-K · filed 2025-02-19 | |||
| 2024-09-30 | $275.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $408.00M derived: sum of 2 quarters · filed 2025-10-30 | $525.10M 10-Q · filed 2025-10-30 | $781.30M derived: sum of 4 quarters · filed 2026-02-12 | ||||
| 2024-06-30 | $133.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $250.10M 10-Q · filed 2025-08-07 | $506.30M derived: sum of 3 quarters · filed 2026-02-12 | $637.70M derived: sum of 4 quarters · filed 2026-02-12 | ||||
| 2024-03-31 | $117.10M 10-Q · filed 2025-05-01 | $373.30M derived: sum of 2 quarters · filed 2026-02-12 | $504.70M derived: sum of 3 quarters · filed 2026-02-12 | $702.10M derived: sum of 4 quarters · filed 2026-02-12 | ||||
| 2023-12-31 | $256.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-12 | $387.60M derived: sum of 2 quarters · filed 2026-02-12 | $585.00M derived: sum of 3 quarters · filed 2026-02-12 | $731.00M 10-K · filed 2026-02-12 | $730.80M 10-K · filed 2024-02-21 | |||
| 2023-09-30 | $131.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | $328.80M derived: sum of 2 quarters · filed 2024-10-30 | $474.80M 10-Q · filed 2024-10-30 | $600.90M derived: sum of 4 quarters · filed 2025-02-19 | ||||
| 2023-06-30 | $197.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $343.40M 10-Q · filed 2024-08-08 | $469.50M derived: sum of 3 quarters · filed 2025-02-19 | $692.20M derived: sum of 4 quarters · filed 2025-02-19 | ||||
| 2023-03-31 | $146.00M 10-Q · filed 2024-04-30 | $272.10M derived: sum of 2 quarters · filed 2025-02-19 | $494.80M derived: sum of 3 quarters · filed 2025-02-19 | $629.50M derived: sum of 4 quarters · filed 2025-02-19 | ||||
| 2022-12-31 | $126.10M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-19 | $348.80M derived: sum of 2 quarters · filed 2025-02-19 | $483.50M derived: sum of 3 quarters · filed 2025-02-19 | $600.20M 10-K · filed 2025-02-19 | ||||
| 2022-09-30 | $222.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $357.40M derived: sum of 2 quarters · filed 2023-11-02 | $474.10M 10-Q · filed 2023-11-02 | |||||
| 2022-06-30 | $134.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $251.40M 10-Q · filed 2023-08-08 | ||||||
| 2022-03-31 | $116.70M 10-Q · filed 2023-04-27 | |||||||
| 2021-12-31 | $929.90M 10-K · filed 2024-02-21 | |||||||
| 2020-12-31 | $358.70M 10-K · filed 2023-02-22 | |||||||
| 2019-12-31 | $247.50M 10-K · filed 2022-02-23 | |||||||
| 2018-12-31 | $837.90M 10-K · filed 2021-02-17 | |||||||
| 2017-12-31 | $4.61B 10-K · filed 2020-02-19 | |||||||
| 2016-12-31 | $4.35B 8-K · filed 2019-10-24 | |||||||
| 2015-12-31 | $3.23B 10-K · filed 2018-02-20 | |||||||
| 2014-12-31 | $9.80B 10-K · filed 2017-02-21 | |||||||
| 2013-12-31 | $14.04B 10-K · filed 2016-02-19 | |||||||
| 2013-06-30 | $4.61B derived: 10-Q 6 month − 10-Q 3 month · filed 2013-07-26 | $6.48B 10-Q · filed 2013-07-26 | $8.59B derived: sum of 3 quarters · filed 2015-02-19 | $10.62B derived: sum of 4 quarters · filed 2015-02-19 | ||||
| 2013-03-31 | $1.86B 10-Q · filed 2013-04-26 | $3.97B derived: sum of 2 quarters · filed 2015-02-19 | $6.00B derived: sum of 3 quarters · filed 2015-02-19 | $7.32B derived: sum of 4 quarters · filed 2015-02-19 | ||||
| 2012-12-31 | $2.11B derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-19 | $4.14B derived: sum of 2 quarters · filed 2015-02-19 | $5.46B derived: sum of 3 quarters · filed 2015-02-19 | $7.62B 10-K · filed 2015-02-19 | ||||
| 2012-09-30 | $2.03B derived: 10-Q 9 month − 10-Q 6 month · filed 2012-10-26 | $3.35B derived: sum of 2 quarters · filed 2013-07-26 | $5.51B 10-Q · filed 2012-10-26 | $7.31B derived: sum of 4 quarters · filed 2014-02-19 | ||||
| 2012-06-30 | $1.32B derived: 10-Q 6 month − 10-Q 3 month · filed 2013-07-26 | $3.48B 10-Q · filed 2013-07-26 | $5.28B derived: sum of 3 quarters · filed 2014-02-19 | $6.30B derived: sum of 4 quarters · filed 2014-02-19 | ||||
| 2012-03-31 | $2.16B 10-Q · filed 2013-04-26 | $3.96B derived: sum of 2 quarters · filed 2014-02-19 | $4.98B derived: sum of 3 quarters · filed 2014-02-19 | $6.38B derived: sum of 4 quarters · filed 2014-02-19 | ||||
| 2011-12-31 | $1.80B derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-19 | $2.82B derived: sum of 2 quarters · filed 2014-02-19 | $4.22B derived: sum of 3 quarters · filed 2014-02-19 | $4.46B 10-K · filed 2014-02-19 | ||||
| 2011-09-30 | $1.02B derived: 10-Q 9 month − 10-Q 6 month · filed 2012-10-26 | $2.42B derived: sum of 2 quarters · filed 2012-10-26 | $2.66B 10-Q · filed 2012-10-26 | $3.21B derived: sum of 4 quarters · filed 2013-02-21 | ||||
| 2011-06-30 | $1.40B derived: 10-Q 6 month − 10-Q 3 month · filed 2012-07-27 | $1.64B 10-Q · filed 2012-07-27 | $2.19B derived: sum of 3 quarters · filed 2013-02-21 | $2.45B derived: sum of 4 quarters · filed 2013-02-21 | ||||
| 2011-03-31 | $238.30M 10-Q · filed 2012-04-30 | $787.30M derived: sum of 2 quarters · filed 2013-02-21 | $1.05B derived: sum of 3 quarters · filed 2013-02-21 | $1.25B derived: sum of 4 quarters · filed 2013-02-21 | ||||
| 2010-12-31 | $549.00M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-21 | $815.00M derived: sum of 2 quarters · filed 2013-02-21 | $1.01B derived: sum of 3 quarters · filed 2013-02-21 | $1.07B 10-K · filed 2013-02-21 | ||||
| 2010-09-30 | $266.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-28 | $461.00M derived: sum of 2 quarters · filed 2011-10-28 | $518.20M 10-Q · filed 2011-10-28 | $621.20M derived: sum of 4 quarters · filed 2012-02-24 | ||||
| 2010-06-30 | $195.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-07-29 | $252.20M 10-Q · filed 2011-07-29 | $355.20M derived: sum of 3 quarters · filed 2012-02-24 | $561.70M derived: sum of 4 quarters · filed 2012-02-24 | ||||
| 2010-03-31 | $57.20M 10-Q · filed 2011-04-29 | $160.20M derived: sum of 2 quarters · filed 2012-02-24 | $366.70M derived: sum of 3 quarters · filed 2012-02-24 | $421.80M derived: sum of 4 quarters · filed 2012-02-24 | ||||
| 2009-12-31 | $103.00M derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-24 | $309.50M derived: sum of 2 quarters · filed 2012-02-24 | $364.60M derived: sum of 3 quarters · filed 2012-02-24 | $432.30M 10-K · filed 2012-02-24 | ||||
| 2009-09-30 | $206.50M derived: 10-Q 9 month − 10-Q/A 6 month · filed 2010-10-29 | $261.60M derived: sum of 2 quarters · filed 2010-10-29 | $329.30M 10-Q · filed 2010-10-29 | -$329.30M 10-Q · filed 2009-10-30 | $4.04B derived: sum of 4 quarters · filed 2011-02-22 | |||
| 2009-06-30 | $55.10M derived: 10-Q/A 6 month − 10-Q 3 month · filed 2010-08-02 | $122.80M 10-Q/A · filed 2010-08-02 | -$122.80M 10-Q · filed 2009-07-31 | $3.83B derived: sum of 3 quarters · filed 2011-02-22 | $3.51B derived: sum of 4 quarters · filed 2011-02-22 | |||
| 2009-03-31 | $67.70M 10-Q · filed 2010-07-30 | $3.78B derived: sum of 2 quarters · filed 2011-02-22 | $3.46B derived: sum of 3 quarters · filed 2011-02-22 | |||||
| 2008-12-31 | $3.71B derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-22 | $3.39B derived: sum of 2 quarters · filed 2011-02-22 | $2.41B 10-K · filed 2011-02-22 | |||||
| 2008-09-30 | -$316.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2009-10-30 | -$1.30B 10-Q · filed 2009-10-30 | ||||||
| 2008-06-30 | -$979.30M 10-Q · filed 2009-07-31 | |||||||
| 2007-12-31 | $750.70M 10-K · filed 2010-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Akari Therapeutics Plc (AKTX) | $1,527.991B | -47,921.42 | |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |